高级检索
    马丹, 高振宇. 贝前列素钠联合环磷酰胺治疗肾病综合征病人的短、中期随访研究[J]. 蚌埠医科大学学报, 2020, 45(3): 355-359, 362. DOI: 10.13898/j.cnki.issn.1000-2200.2020.03.019
    引用本文: 马丹, 高振宇. 贝前列素钠联合环磷酰胺治疗肾病综合征病人的短、中期随访研究[J]. 蚌埠医科大学学报, 2020, 45(3): 355-359, 362. DOI: 10.13898/j.cnki.issn.1000-2200.2020.03.019
    shu
    MA Dan, GAO Zhen-yu. Study on short and mid-term effects of bereprost sodium combined with cyclophosphamide in the treatment of nephrotic syndrome[J]. Journal of Bengbu Medical University, 2020, 45(3): 355-359, 362. DOI: 10.13898/j.cnki.issn.1000-2200.2020.03.019
    Citation: MA Dan, GAO Zhen-yu. Study on short and mid-term effects of bereprost sodium combined with cyclophosphamide in the treatment of nephrotic syndrome[J]. Journal of Bengbu Medical University, 2020, 45(3): 355-359, 362. DOI: 10.13898/j.cnki.issn.1000-2200.2020.03.019
    shu

    贝前列素钠联合环磷酰胺治疗肾病综合征病人的短、中期随访研究

    Study on short and mid-term effects of bereprost sodium combined with cyclophosphamide in the treatment of nephrotic syndrome

      摘要
    • 摘要:
      目的分析贝前列素钠与环磷酰胺联合治疗肾病综合征（nephrotic syndrome，NS）病人的短、中期效果。
      方法选取2015年1月至2017年5月96例NS病人，随机分组进行对照研究，对照组（n=48）予以常规综合治疗，观察组（n=48）在此基础上予以贝前列素钠与环磷酰胺联合治疗，比较2组疾病控制率、复发率、肾功能指标肌酐清除率（CCR）、白蛋白（ALB）、肌酐（Scr）、24 h尿蛋白排泄率（UAER）、尿素氮（BUN）、血脂指标三酰甘油（TG）、总胆固醇（TC）、凝血指标D-二聚体（D-D）、纤维蛋白原（FIB）、P-糖蛋白170（P-gp170）水平及不良反应发生率。
      结果观察组疾病控制率优于对照组（P < 0.01），治疗后6个月、1年复发率（2.08%、4.17%）低于对照组（16.67%、18.75%）（P < 0.05）；2组治疗后CCR、ALB均明显高于治疗前（P < 0.01），Scr、UAER、BUN均明显低于治疗前（P < 0.01）；观察组治疗后CCR、ALB明显高于对照组（P < 0.01），Scr、UAER、BUN明显低于对照组（P < 0.01）；治疗后观察组TG、TC均低于明显对照组（P < 0.01）。2组治疗后TG、TC均明显低于治疗前（P < 0.01）；2组治疗后P-gp170水平均较治疗前升高，但观察组升高幅度小于对照组（P < 0.01）。观察组不良反应发生率4.17%与对照组8.33%相比，差异无统计学意义（P>0.05）。
      结论贝前列素钠与环磷酰胺联合治疗NS，能改善病人机体多药耐药现象，优化血脂代谢，改善肾功能与凝血功能，提高疾病控制率，减少疾病的复发，安全可靠。

       

      Abstract:
      Objective:To analyze the short and mid-term effects of beraprost sodium combined with cyclophosphamide in the treatment of nephrotic syndrome(NS).
      MethodsNinety-six patients with NS from January 2015 to May 2017 were randomly divided into the control group and observation group(48 cases in each group).The control group was treated with the routine comprehensive method, and the observation group was additionally treated with beraprostis sodium combined with cyclophosphamide based on control group.The disease control rate, recurrence rate, renal function indexcreatinine clearance(CCR), albumin (ALB), creatinine (Scr), 24h urinary protein excretion rate(UAER) and urea nitrogen (BUN), blood lipid indicatorstriglyceride(TG) and total cholesterol(TC), coagulation parametersD-dimer(D-D) and fibrinogen(FIB), P-glycoprotein 170(P-gp170) and incidence arte of adverse reactions were compared between two groups.
      ResultsThe disease control rate(93.75%) in observation group was better than that in control group(68.75%)(P < 0.01).After 6 months and 1 year of treatment, the recurrence rates in observation group(2.08% and 4.17%) were lower than those in control group(16.67% and 18.75%), respectively(P < 0.05).After treatment, the CCR and ALB levels in observation group were significnatly higher than those in control group, while the levels of Scr, UAER and BUN in observation group were significnatly lower than those in control group(P < 0.05).After treatment, the levels of TG and TC in observation group were significnatly lower than those in control group(P < 0.05), and the levels of TG and TC in two groups were significnatly lower than those before treatment(P < 0.05).After treatment, the P-gp170 levels in two groups increased compared with before treatment, but the increasing degree of which in observation group was smaller than that in control group(P < 0.05).There was no statistical significance in the incidence rate of adverse reactions between the observation group(4.17%) and control group(8.33%) (P>0.05).
      ConclusionsThe bereprost sodium combined with cyclophosphamide in the treatment of NS can improve the multidrug resistance, optimize blood lipid metabolism, improve renal function and coagulation function, increase disease control rate, reduce the recurrence of the disease, and is safe and reliable.

       

      • HTML全文
      • 参考文献(32)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回